Journal article

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)

Abstract:: Background: The 20-year UK Prospective Diabetes Study showed major clinical benefits for people with newly diagnosed type 2 diabetes randomly allocated to intensive glycaemic control with sulfonylurea or insulin therapy or metformin therapy, compared with conventional glycaemic control. 10-year post-trial follow-up identified enduring and emerging glycaemic and metformin legacy treatment effects. We aimed to determine whether these effects would wane by extending follow-up...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Adler, A. I., Coleman, R. L., Leal, J., Whiteley, W. N., Clarke, P., & Holman, R. R. (2024). Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet, 404(10448), 145–155.

MLA Style

Adler, A. I., et al. “Post-Trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended from 10 Years to 24 Years (UKPDS 91).” Lancet, vol. 404, no. 10448, Elsevier, 2024, pp. 145–55.

Chicago Style

Adler, AI, RL Coleman, J Leal, WN Whiteley, P Clarke, and RR Holman. 2024. “Post-Trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended from 10 Years to 24 Years (UKPDS 91).” Lancet 404 (10448): 145–55.
Share
Print

Access Document

Files:: Adler_et_al_2024_Post-trial_monitoring_of.pdf

(Preview, Version of record, pdf, 934.6KB, Terms of use)

Publisher copy:: 10.1016/s0140-6736(24)00537-3

Authors

+ Adler, AI More by this author

Institution:: University of Oxford
Division:: MSD
Department:: RDM
Sub department:: OCDEM
Role:: Author
ORCID:: 0000-0002-2797-3385

+ Coleman, RL More by this author

Institution:: University of Oxford
Division:: MSD
Department:: RDM
Sub department:: OCDEM
Role:: Author
ORCID:: 0000-0002-5194-8550

+ Leal, J More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Primary Care Health Sciences
Role:: Author

+ Whiteley, WN More by this author

Role:: Author

+ Clarke, P More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Biomedical Services
Role:: Author

More authors...

+ Department of Health and Social Care More from this funder

Publisher:: Elsevier
Journal:: Lancet More from this journal
Volume:: 404
Issue:: 10448
Pages:: 145-155
Place of publication:: England
Publication date:: 2024-05-17
Acceptance date:: 2024-03-13
DOI:: 10.1016/s0140-6736(24)00537-3
EISSN:: 1474-547X
ISSN:: 0140-6736
Pmid:: 38772405

Language:: English
Keywords:: patient safety

diabetes

aging

metabolic and endocrine

clinical trials and supportive activities

clinical research
Pubs id:: 1997914
Local pid:: pubs:1997914
Deposit date:: 2024-06-04

Terms of use

Copyright holder:: Adler et al.
Copyright date:: 2024
Rights statement:: © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP